New Study Validates Stability of Polio Vaccine
Researchers from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) have conducted a significant international study, revealing promising findings regarding the genetic stability of the novel live-attenuated oral poliovirus type 2 vaccine (nOPV2). Published in the esteemed journal Nature Microbiology, the study highlights nOPV2’s effectiveness in global efforts to eradicate polio.
Study Overview
This collaborative research involved institutions from several countries, including Uganda, the UK, Israel, France, the Netherlands, the United States, and the World Health Organization. The study provides critical insights into the vaccine’s evolution after administration, showcasing its enhanced stability when compared to older oral polio vaccines.
Key Findings
Analysis was performed on 231 poliovirus type 2 isolates collected from stool and sewage samples in Uganda between January 2022 and March 2023, following vaccination campaigns using nOPV2. Researchers concluded that nOPV2 exhibits greater genetic stability than its predecessor, the Sabin oral polio vaccine. Notably, changes in the vaccine’s genetic structure, particularly regarding the stabilization of the primary genetic domain responsible for its attenuation, were confirmed.
Despite these advancements, the study did detect a rare double recombinant strain that emerged through genetic recombination. Though laboratory tests indicated this strain had increased neurovirulence, it did not widely spread, likely due to extensive vaccination coverage in the affected regions.
Expert Commentary
Dr. Javier Martin, Head of the Polio Laboratory at the MHRA and a co-author of the study, stated, “This study confirms nOPV2 is performing as designed to interrupt polio outbreaks whilst reducing the risk of new vaccine-derived outbreaks. Uganda successfully interrupted circulating vaccine-derived poliovirus transmission following two nationwide nOPV2 campaigns reaching approximately 20 million children.”
MHRA’s Role
The MHRA’s WHO Global Specialized Laboratory for Polio played a pivotal role in the study, employing advanced sequencing technologies to perform comprehensive whole-genome analysis of viral samples. Their efforts were supported by funding from various health institutions, including the National Institute for Health Research (NIHR) and the Bill and Melinda Gates Foundation.
Global Implications
The findings indicate a lowered risk of dangerous virus reversion with the use of nOPV2 compared to previous oral polio vaccines. However, they also underscore the necessity for ongoing surveillance systems to promptly detect and address rare genetic mutations. This research backs the continued application of nOPV2 alongside inactivated polio vaccines, in conjunction with vigorous immunisation initiatives and vigilant monitoring, as integral to global polio eradication efforts.
Background
The World Health Organization characterizes poliovirus transmission as a Public Health Emergency of International Concern. As global efforts to eliminate polio advance, innovative vaccine strategies become crucial in countering potential resurgence.
Source: official statements, news agencies, and public reports.
https://www.gov.uk/government/news/mhra-scientists-contribute-to-international-study-on-novel-oral-polio-vaccine-stability
